A feasibility study of [ 11C]SA4503-PET for evaluating sigma 1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma 1 and dopamine D 2-like receptors

Annals of Nuclear Medicine

Volumn 20, Issue 8, 2006, Pages 569-573

  Ishiwata, Kiichi ^a   Oda, Kenji ^b   Sakata, Muneyuki ^c   Kimura, Yuichi ^a   Kawamura, Kazunori ^a   Oda, Keiichi ^a   Sasaki, Toru ^a   Naganawa, Mika ^a,d   Chihara, Kunihiro ^c   Okubo, Yoshiro ^e   Ishii, Kenji ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^d Nippon Medical School ^*

^e NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

11C SA4503; Haloperidol; Positron emission tomography; Receptor occupancy; Sigma 1 receptor

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; RACLOPRIDE C 11; SIGMA 1 OPIATE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PIPERAZINE DERIVATIVE; SIGMA OPIATE RECEPTOR;

ADULT; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; DRUG BINDING; FEASIBILITY STUDY; HUMAN; HUMAN EXPERIMENT; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; BRAIN; INSTRUMENTATION; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN BINDING; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE ANTAGONISTS; FEASIBILITY STUDIES; HALOPERIDOL; HUMANS; MALE; NOOTROPIC AGENTS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, SIGMA; TIME FACTORS;

EID: 33751411962     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF03026824     Document Type: Article

References (17)

1. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl 4): 83-89.
2. Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L. Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 1998; 13 (Suppl 3): S15-S20.
3. 11C-doxepin in a placebo-ontrolled crossover study design in healthy volunteers: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 2006; 61: 16-26.
4. Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996; 58: 721-734.
5. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990; 42: 355-402.
6. Hashimoto K, Ishiwata K. Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Design 2006; 12: 3915-3928.
7. 1 receptors. Nucl Med Biol 2000; 27: 255-261.
8. 1 receptors in the cat brain. Ann Nucl Med 2000; 14: 285-292.
9. 1 receptors in the aged monkey brain. Neurobiol Aging 2003; 24: 745-752.
10. 1 receptors in Parkinson's disease. Acta Neurologica 2005; 112: 103-107.
11. 2-like receptor ligands. Nucl Med Biol 2003: 30: 429-434.
12. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial fiel-of-view PET scanner: SET-2400W. Ann Nucl Med 1997; 11: 307-313.
13. 11C]methyl triflate. J Label Compds Radiopharm 1999; 42: 1183-1193.
14. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 1997; 16: 145-158.
15. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 1997; 6: 279-287.
16. Frieboes RM, Murck H, Antonijevic I, Kraus T, Hinze-Selch D, Pollmacher T, et al. Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls. Psychopharmacology (Berl) 1999; 141: 107-110.
17. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Meta 1990; 10: 740-747.